Bone Morphogenetic Protein 6 Attenuates Psoriasis Pathogenesis by Suppressing Th17 Cell Differentiation

Area of Science:

• Immunology
• Cell Biology
• Dermatology

Background:

• Bone morphogenetic protein (BMP) signaling influences T cell differentiation, with BMP6 promoting Th1 cells.
• The role of BMP6 in T helper 17 (Th17) cell differentiation and its therapeutic potential in psoriasis remain unclear.
• Dysregulated Th17 cell differentiation is implicated in the pathogenesis of psoriasis, an autoimmune skin disease.

Purpose of the Study:

• To investigate the effect of BMP6 on Th17 cell differentiation.
• To explore the underlying mechanisms of BMP6 action on Th17 cells.
• To evaluate the therapeutic potential of BMP6 in a mouse model of psoriasis.

Main Methods:

• In vitro intervention of Th17 cells with BMP6, assessed by flow cytometry, qRT-PCR, and ELISA.
• Analysis of signaling pathways (Smad1/5/9) using Western blotting and RNA sequencing.
• In vivo experiments using an imiquimod-induced psoriatic mouse model treated with BMP6.

Main Results:

• BMP6 treatment suppressed Th17 differentiation in vitro via the Smad1/5/9 pathway.
• BMP6 impaired mitochondrial metabolism in Th17 cells.
• Pharmacological administration of BMP6 attenuated psoriasis progression and reduced pathogenic Th17 cell frequency in mice.

Conclusions:

• BMP6 inhibits Th17 cell differentiation and offers a potential therapeutic strategy for Th17-driven autoimmune diseases like psoriasis.
• BMP6 acts through the Smad1/5/9 pathway and affects mitochondrial metabolism in Th17 cells.
• These findings provide a theoretical basis for the clinical application of BMP6 in treating autoimmune conditions.